{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T15:07:56Z","timestamp":1787843276603,"version":"build-2784847793"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"DOI":"10.1186\/s40001-025-02858-z","type":"journal-article","created":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:27:52Z","timestamp":1754008072000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Multinational association for supportive care in cancer (MASCC) versus clinical index of stable febrile neutropenia (CISNE): evaluation of predictive performance and clinical utility in patients with febrile neutropenia"],"prefix":"10.1186","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8509-0660","authenticated-orcid":false,"given":"S\u00fcleyman","family":"Alpar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8166-659X","authenticated-orcid":false,"given":"Sarper","family":"Y\u0131lmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,1]]},"reference":[{"issue":"2","key":"2858_CR1","first-page":"55","volume":"32","author":"F Escrihuela-Vidal","year":"2019","unstructured":"Escrihuela-Vidal F, Laporte J, Albasanz-Puig A, Gudiol C. Update on the management of febrile neutropenia in hematologic patients. Rev Esp Quimioter. 2019;32(2):55\u20138.","journal-title":"Rev Esp Quimioter"},{"key":"2858_CR2","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1093\/oncolo\/oyac074","volume":"27","author":"R Boccia","year":"2022","unstructured":"Boccia R, Glaspy J, Crawford J, Aapro M. Chemotherapy-induced neutropenia and febrile neutropenia in the US: a beast of burden that needs to be tamed? Oncologist. 2022;27:625\u201336.","journal-title":"Oncologist"},{"key":"2858_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2025.101214","volume":"51","author":"M Sandherr","year":"2024","unstructured":"Sandherr M, Stemler J, Schalk E, et al. update of the AGIHO guideline on diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients with solid tumours and hematological malignancies. Lancet Reg Health Eur. 2024;51: 101214.","journal-title":"Lancet Reg Health Eur"},{"key":"2858_CR4","doi-asserted-by":"publisher","first-page":"6","DOI":"10.37897\/RJID.2023.1.1","volume":"26","author":"DV Mangaloiu","year":"2023","unstructured":"Mangaloiu DV, Staicu ID, Negru AR, et al. Management of the febrile neutropenic patient in 2023. Ro J Infect Dis. 2023;26:6.","journal-title":"Ro J Infect Dis"},{"key":"2858_CR5","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1097\/01.JAA.0000000000000054","volume":"37","author":"J Cossey","year":"2024","unstructured":"Cossey J, Cote MCB. Evaluation and management of febrile neutropenia in patients with cancer. JAAPA. 2024;37:16\u201320.","journal-title":"JAAPA"},{"key":"2858_CR6","doi-asserted-by":"publisher","first-page":"pky053","DOI":"10.1093\/jncics\/pky053","volume":"2","author":"T Aagaard","year":"2018","unstructured":"Aagaard T, Roen A, Reekie J, et al. Development and validation of a risk score for febrile neutropenia after chemotherapy in patients with cancer: the FENCE score. JNCI Cancer Spectr. 2018;2:pky053.","journal-title":"JNCI Cancer Spectr"},{"key":"2858_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2020.102922","volume":"149","author":"B Zheng","year":"2020","unstructured":"Zheng B, Toarta C, Cheng W, Taljaard M, Reaume N, Perry JJ. Accuracy of the multinational association of supportive care in cancer (MASCC) and clinical index of stable febrile neutropenia (CISNE) scores for predicting serious complications in adult patients with febrile neutropenia: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2020;149: 102922.","journal-title":"Crit Rev Oncol Hematol"},{"key":"2858_CR8","doi-asserted-by":"publisher","first-page":"3038","DOI":"10.1200\/JCO.2000.18.16.3038","volume":"18","author":"J Klastersky","year":"2000","unstructured":"Klastersky J, Paesmans M, Rubenstein EB, et al. The MASCC risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000;18:3038\u201351.","journal-title":"J Clin Oncol"},{"key":"2858_CR9","first-page":"5905","volume":"29","author":"PV Bhardwaj","year":"2021","unstructured":"Bhardwaj PV, Emmich M, Knee A, et al. Use of MASCC score in the inpatient management of febrile neutropenia: a single-center retrospective study. Support Care Cancer. 2021;29:5905\u201314.","journal-title":"Support Care Cancer"},{"key":"2858_CR10","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s12288-016-0730-7","volume":"33","author":"M Taj","year":"2017","unstructured":"Taj M, Nadeem M, Maqsood S, Shah T, Farzana T, Shamsi TS. Validation of MASCC score for risk stratification in patients of hematological disorders with febrile neutropenia. Indian J Hematol Blood Transfus. 2017;33:355\u201360.","journal-title":"Indian J Hematol Blood Transfus"},{"key":"2858_CR11","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1200\/JCO.2014.57.2347","volume":"33","author":"A Carmona-Bayonas","year":"2015","unstructured":"Carmona-Bayonas A, Jimenez-Fonseca P, Virizuela Echaburu J, et al. Prediction of serious complications in patients with seemingly stable febrile neutropenia: validation of the CISNE in the FINITE study. J Clin Oncol. 2015;33:465\u201371.","journal-title":"J Clin Oncol"},{"key":"2858_CR12","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1038\/bjc.2011.284","volume":"105","author":"A Carmona-Bayonas","year":"2011","unstructured":"Carmona-Bayonas A, G\u00f3mez J, Gonz\u00e1lez-Billalabeitia E, et al. Prognostic evaluation of febrile neutropenia in apparently stable adult cancer patients. Br J Cancer. 2011;105:612\u20137.","journal-title":"Br J Cancer"},{"key":"2858_CR13","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1038\/bjc.2016.118","volume":"114","author":"PJ Fonseca","year":"2016","unstructured":"Fonseca PJ, Carmona-Bayonas A, Garc\u00eda IM, et al. A nomogram for predicting complications in patients with solid tumours and seemingly stable febrile neutropenia. Br J Cancer. 2016;114:1191\u20138.","journal-title":"Br J Cancer"},{"key":"2858_CR14","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1177\/1078155213492450","volume":"20","author":"D Weycker","year":"2014","unstructured":"Weycker D, Barron R, Kartashov A, Legg J, Lyman GH. Incidence, treatment, and consequences of chemotherapy-induced febrile neutropenia in the inpatient and outpatient settings. J Oncol Pharm Pract. 2014;20:190\u20138.","journal-title":"J Oncol Pharm Pract"},{"key":"2858_CR15","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1200\/JCO.2012.45.8661","volume":"31","author":"CR Flowers","year":"2013","unstructured":"Flowers CR, Seidenfeld J, Bow EJ, et al. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: ASCO clinical practice guideline. J Clin Oncol. 2013;31:794\u2013810.","journal-title":"J Clin Oncol"},{"key":"2858_CR16","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.annemergmed.2016.11.007","volume":"69","author":"CJ Coyne","year":"2017","unstructured":"Coyne CJ, Le V, Brennan JJ, et al. Application of the MASCC and CISNE risk-stratification scores to identify low-risk febrile neutropenic patients in the emergency department. Ann Emerg Med. 2017;69:755\u201364.","journal-title":"Ann Emerg Med"},{"key":"2858_CR17","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1200\/JCO.2017.77.6211","volume":"36","author":"RA Taplitz","year":"2018","unstructured":"Taplitz RA, Kennedy EB, Bow EJ, et al. Outpatient management of fever and neutropenia in adults treated for malignancy: ASCO and IDSA clinical practice guideline update. J Clin Oncol. 2018;36:1443\u201353.","journal-title":"J Clin Oncol"},{"key":"2858_CR18","first-page":"341","volume":"56","author":"S Shakinah","year":"2024","unstructured":"Shakinah S, Nelwan EJ, Lubis AM, Sinto R, Lie KC. Comparison of CISNE and MASCC score in predicting complications on post chemotherapy febrile neutropenia. Acta Med Indones. 2024;56:341\u20138.","journal-title":"Acta Med Indones"},{"key":"2858_CR19","first-page":"1465","volume":"26","author":"S Ahn","year":"2018","unstructured":"Ahn S, Rice TW, Yeung SJ, Cooksley T. Comparison of the MASCC and CISNE scores for identifying low-risk neutropenic fever patients: analysis of data from three emergency departments. Support Care Cancer. 2018;26:1465\u201370.","journal-title":"Support Care Cancer"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-02858-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-025-02858-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-02858-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T10:36:20Z","timestamp":1757327780000},"score":1,"resource":{"primary":{"URL":"https:\/\/eurjmedres.biomedcentral.com\/articles\/10.1186\/s40001-025-02858-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2858"],"URL":"https:\/\/doi.org\/10.1186\/s40001-025-02858-z","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,1]]},"assertion":[{"value":"6 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was obtained from the institutional review boards of Memorial Bah\u00e7elievler Hospital (Approval No: 148, Date: 27.03.2025). Due to the retrospective nature of the study, the ethics committee waived the requirement for informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"692"}}